International Stem Cell (ISCO) Revenue (2010 - 2026)

International Stem Cell (ISCO) has reported Revenue for 17 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 9.32% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $9.6 million, a 4.84% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, changed 0.17% from the prior year.
• Revenue was $2.7 million for Q2 2026 at International Stem Cell, up from $2.2 million in the prior quarter.
• Over five years, Revenue peaked at $2.7 million in Q2 2026 and troughed at $1.7 million in Q3 2022.
• A 5-year average of $2.2 million and a median of $2.1 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue jumped 31.85% in 2022 and retreated 22.26% in 2023, its largest moves.
• Over 5 years, Revenue stood at $2.4 million in 2022, then decreased by 22.26% to $1.9 million in 2023, then grew by 29.49% to $2.4 million in 2024, then slipped by 11.9% to $2.2 million in 2025, then rose by 24.13% to $2.7 million in 2026.
• The last three Revenue figures came in at $2.7 million (Q2 2026), $2.2 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.